UBS Maintains Neutral on AbbVie, Raises Price Target to $275
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.